Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Novel missense mutations in the FOXC2 gene alter transcriptional activity

Identifieur interne : 006E64 ( Istex/Corpus ); précédent : 006E63; suivant : 006E65

Novel missense mutations in the FOXC2 gene alter transcriptional activity

Auteurs : M. A. M. Van Steensel ; R. J. Damstra ; M. Heitink ; R. S. Bladergroen ; J. Veraart ; Peter M. Steijlen ; M. Van Geel

Source :

RBID : ISTEX:EBEC66DF465A6B45C9A38C952C033F01B5A0B702

Abstract

Mutations in the FOXC2 gene that codes for a forkhead transcription factor are associated with primary lymphedema that usually develops around puberty. Associated abnormalities include distichiasis and, very frequently, superficial and deep venous insufficiency. Most mutations reported so far either truncate the protein or are missense mutations in the forkhead domain causing a loss of function. The haplo‐insufficient state is associated with lymphatic hyperplasia in mice as well as in humans. We analyzed the FOXC2 gene in 288 patients with primary lymphedema and found 11 pathogenic mutations, of which 9 are novel. Of those, 5 were novel missense mutations of which 4 were located outside of the forkhead domain. To examine their pathogenic potential we performed a transactivation assay using a luciferase reporter construct driven by FOXC1 response elements. We found that the mutations outside the forkhead domain cause a gain of function as measured by luciferase activity. Patient characteristics conform to previous reports with the exception of distichiasis, which was found in only 2 patients out of 11. FOXC2 mutations causing lymphedema‐distichiasis syndrome reported thus far result in haplo‐insufficiency and lead to lymphatic hyperplasia. Our results suggest that gain‐of‐function mutations may also cause lymphedema. One would expect that in this case, lymphatic hypoplasia would be the underlying abnormality. Patients with activating mutations might present with Meige disease. © 2009 Wiley‐Liss, Inc.

Url:
DOI: 10.1002/humu.21127

Links to Exploration step

ISTEX:EBEC66DF465A6B45C9A38C952C033F01B5A0B702

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Novel missense mutations in the FOXC2 gene alter transcriptional activity</title>
<author>
<name sortKey="Van Steensel, M A M" sort="Van Steensel, M A M" uniqKey="Van Steensel M" first="M. A. M." last="Van Steensel">M. A. M. Van Steensel</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Department of Dermatology, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Damstra, R J" sort="Damstra, R J" uniqKey="Damstra R" first="R. J." last="Damstra">R. J. Damstra</name>
<affiliation>
<mods:affiliation>Nij Smellinghe Hospital, Drachten, the Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Heitink, M" sort="Heitink, M" uniqKey="Heitink M" first="M." last="Heitink">M. Heitink</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Bladergroen, R S" sort="Bladergroen, R S" uniqKey="Bladergroen R" first="R. S." last="Bladergroen">R. S. Bladergroen</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Veraart, J" sort="Veraart, J" uniqKey="Veraart J" first="J." last="Veraart">J. Veraart</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Steijlen, Peter M" sort="Steijlen, Peter M" uniqKey="Steijlen P" first="Peter M." last="Steijlen">Peter M. Steijlen</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Van Geel, M" sort="Van Geel, M" uniqKey="Van Geel M" first="M." last="Van Geel">M. Van Geel</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:EBEC66DF465A6B45C9A38C952C033F01B5A0B702</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1002/humu.21127</idno>
<idno type="url">https://api.istex.fr/document/EBEC66DF465A6B45C9A38C952C033F01B5A0B702/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">006E64</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">006E64</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Novel missense mutations in the
<hi rend="italic">FOXC2</hi>
gene alter transcriptional activity
<ref type="note" target="#fn1"></ref>
</title>
<author>
<name sortKey="Van Steensel, M A M" sort="Van Steensel, M A M" uniqKey="Van Steensel M" first="M. A. M." last="Van Steensel">M. A. M. Van Steensel</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>Department of Dermatology, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Damstra, R J" sort="Damstra, R J" uniqKey="Damstra R" first="R. J." last="Damstra">R. J. Damstra</name>
<affiliation>
<mods:affiliation>Nij Smellinghe Hospital, Drachten, the Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Heitink, M" sort="Heitink, M" uniqKey="Heitink M" first="M." last="Heitink">M. Heitink</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Bladergroen, R S" sort="Bladergroen, R S" uniqKey="Bladergroen R" first="R. S." last="Bladergroen">R. S. Bladergroen</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Veraart, J" sort="Veraart, J" uniqKey="Veraart J" first="J." last="Veraart">J. Veraart</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Steijlen, Peter M" sort="Steijlen, Peter M" uniqKey="Steijlen P" first="Peter M." last="Steijlen">Peter M. Steijlen</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
</author>
<author>
<name sortKey="Van Geel, M" sort="Van Geel, M" uniqKey="Van Geel M" first="M." last="Van Geel">M. Van Geel</name>
<affiliation>
<mods:affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
<affiliation>
<mods:affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Human Mutation</title>
<title level="j" type="alt">HUMAN MUTATION</title>
<idno type="ISSN">1059-7794</idno>
<idno type="eISSN">1098-1004</idno>
<imprint>
<biblScope unit="vol">30</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="E1002">E1002</biblScope>
<biblScope unit="page" to="E1009">E1009</biblScope>
<biblScope unit="page-count">8</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-12">2009-12</date>
</imprint>
<idno type="ISSN">1059-7794</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1059-7794</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Mutations in the FOXC2 gene that codes for a forkhead transcription factor are associated with primary lymphedema that usually develops around puberty. Associated abnormalities include distichiasis and, very frequently, superficial and deep venous insufficiency. Most mutations reported so far either truncate the protein or are missense mutations in the forkhead domain causing a loss of function. The haplo‐insufficient state is associated with lymphatic hyperplasia in mice as well as in humans. We analyzed the FOXC2 gene in 288 patients with primary lymphedema and found 11 pathogenic mutations, of which 9 are novel. Of those, 5 were novel missense mutations of which 4 were located outside of the forkhead domain. To examine their pathogenic potential we performed a transactivation assay using a luciferase reporter construct driven by FOXC1 response elements. We found that the mutations outside the forkhead domain cause a gain of function as measured by luciferase activity. Patient characteristics conform to previous reports with the exception of distichiasis, which was found in only 2 patients out of 11. FOXC2 mutations causing lymphedema‐distichiasis syndrome reported thus far result in haplo‐insufficiency and lead to lymphatic hyperplasia. Our results suggest that gain‐of‐function mutations may also cause lymphedema. One would expect that in this case, lymphatic hypoplasia would be the underlying abnormality. Patients with activating mutations might present with Meige disease. © 2009 Wiley‐Liss, Inc.</div>
</front>
</TEI>
<istex>
<corpusName>wiley</corpusName>
<keywords>
<teeft>
<json:string>mutation</json:string>
<json:string>foxc2</json:string>
<json:string>lymphedema</json:string>
<json:string>missense</json:string>
<json:string>forkhead</json:string>
<json:string>transcriptional</json:string>
<json:string>venous</json:string>
<json:string>foxc2 gene</json:string>
<json:string>lymphatic</json:string>
<json:string>insufficiency</json:string>
<json:string>forkhead domain</json:string>
<json:string>mutant</json:string>
<json:string>luciferase</json:string>
<json:string>saleem</json:string>
<json:string>distichiasis</json:string>
<json:string>transcriptional activity</json:string>
<json:string>maastricht</json:string>
<json:string>varicose veins</json:string>
<json:string>primary lymphedema</json:string>
<json:string>missense mutations</json:string>
<json:string>foxc2 mutations</json:string>
<json:string>deep venous insufficiency</json:string>
<json:string>mutant foxc2</json:string>
<json:string>recurrent erysipelas</json:string>
<json:string>assay</json:string>
<json:string>cause lymphedema</json:string>
<json:string>lymphatic hypoplasia</json:string>
<json:string>maastricht university</json:string>
<json:string>cos7 cells</json:string>
<json:string>luciferase assay</json:string>
<json:string>venous insufficiency</json:string>
</teeft>
</keywords>
<author>
<json:item>
<name>M.A.M. van Steensel</name>
<affiliations>
<json:string>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</json:string>
<json:string>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</json:string>
<json:string>Department of Dermatology, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht</json:string>
</affiliations>
</json:item>
<json:item>
<name>R.J. Damstra</name>
<affiliations>
<json:string>Nij Smellinghe Hospital, Drachten, the Netherlands</json:string>
</affiliations>
</json:item>
<json:item>
<name>M. Heitink</name>
<affiliations>
<json:string>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</json:string>
<json:string>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</json:string>
</affiliations>
</json:item>
<json:item>
<name>R.S. Bladergroen</name>
<affiliations>
<json:string>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</json:string>
<json:string>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</json:string>
</affiliations>
</json:item>
<json:item>
<name>J. Veraart</name>
<affiliations>
<json:string>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</json:string>
<json:string>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</json:string>
</affiliations>
</json:item>
<json:item>
<name>Peter M. Steijlen</name>
<affiliations>
<json:string>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</json:string>
<json:string>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</json:string>
</affiliations>
</json:item>
<json:item>
<name>M. van Geel</name>
<affiliations>
<json:string>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</json:string>
<json:string>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</json:string>
</affiliations>
</json:item>
</author>
<subject>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>FOXC2</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>lymphedema</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>transactivation</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>forkhead</value>
</json:item>
<json:item>
<lang>
<json:string>eng</json:string>
</lang>
<value>Meige</value>
</json:item>
</subject>
<articleId>
<json:string>HUMU21127</json:string>
</articleId>
<language>
<json:string>eng</json:string>
</language>
<originalGenre>
<json:string>shortCommunication</json:string>
</originalGenre>
<abstract>Mutations in the FOXC2 gene that codes for a forkhead transcription factor are associated with primary lymphedema that usually develops around puberty. Associated abnormalities include distichiasis and, very frequently, superficial and deep venous insufficiency. Most mutations reported so far either truncate the protein or are missense mutations in the forkhead domain causing a loss of function. The haplo‐insufficient state is associated with lymphatic hyperplasia in mice as well as in humans. We analyzed the FOXC2 gene in 288 patients with primary lymphedema and found 11 pathogenic mutations, of which 9 are novel. Of those, 5 were novel missense mutations of which 4 were located outside of the forkhead domain. To examine their pathogenic potential we performed a transactivation assay using a luciferase reporter construct driven by FOXC1 response elements. We found that the mutations outside the forkhead domain cause a gain of function as measured by luciferase activity. Patient characteristics conform to previous reports with the exception of distichiasis, which was found in only 2 patients out of 11. FOXC2 mutations causing lymphedema‐distichiasis syndrome reported thus far result in haplo‐insufficiency and lead to lymphatic hyperplasia. Our results suggest that gain‐of‐function mutations may also cause lymphedema. One would expect that in this case, lymphatic hypoplasia would be the underlying abnormality. Patients with activating mutations might present with Meige disease. © 2009 Wiley‐Liss, Inc.</abstract>
<qualityIndicators>
<score>6.584</score>
<pdfVersion>1.5</pdfVersion>
<pdfPageSize>612 x 792 pts (letter)</pdfPageSize>
<refBibsNative>false</refBibsNative>
<abstractCharCount>1525</abstractCharCount>
<pdfWordCount>2920</pdfWordCount>
<pdfCharCount>18889</pdfCharCount>
<pdfPageCount>8</pdfPageCount>
<abstractWordCount>222</abstractWordCount>
</qualityIndicators>
<title>Novel missense mutations in the FOXC2 gene alter transcriptional activity</title>
<genre>
<json:string>brief-communication</json:string>
</genre>
<host>
<title>Human Mutation</title>
<language>
<json:string>unknown</json:string>
</language>
<doi>
<json:string>10.1002/(ISSN)1098-1004</json:string>
</doi>
<issn>
<json:string>1059-7794</json:string>
</issn>
<eissn>
<json:string>1098-1004</json:string>
</eissn>
<publisherId>
<json:string>HUMU</json:string>
</publisherId>
<volume>30</volume>
<issue>12</issue>
<pages>
<first>E1002</first>
<last>E1009</last>
<total>8</total>
</pages>
<genre>
<json:string>journal</json:string>
</genre>
<subject>
<json:item>
<value>Mutation in Brief</value>
</json:item>
</subject>
</host>
<categories>
<wos>
<json:string>science</json:string>
<json:string>genetics & heredity</json:string>
</wos>
<scienceMetrix>
<json:string>health sciences</json:string>
<json:string>biomedical research</json:string>
<json:string>genetics & heredity</json:string>
</scienceMetrix>
<inist>
<json:string>sciences appliquees, technologies et medecines</json:string>
<json:string>sciences biologiques et medicales</json:string>
<json:string>sciences medicales</json:string>
<json:string>ophtalmologie</json:string>
</inist>
</categories>
<publicationDate>2009</publicationDate>
<copyrightDate>2009</copyrightDate>
<doi>
<json:string>10.1002/humu.21127</json:string>
</doi>
<id>EBEC66DF465A6B45C9A38C952C033F01B5A0B702</id>
<score>1</score>
<fulltext>
<json:item>
<extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/EBEC66DF465A6B45C9A38C952C033F01B5A0B702/fulltext/pdf</uri>
</json:item>
<json:item>
<extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/EBEC66DF465A6B45C9A38C952C033F01B5A0B702/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/EBEC66DF465A6B45C9A38C952C033F01B5A0B702/fulltext/tei">
<teiHeader>
<fileDesc>
<titleStmt>
<title level="a" type="main" xml:lang="en">Novel missense mutations in the
<hi rend="italic">FOXC2</hi>
gene alter transcriptional activity
<ref type="note" target="#fn1"></ref>
</title>
</titleStmt>
<publicationStmt>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<availability>
<licence>© 2009 Wiley‐Liss, Inc.</licence>
</availability>
<date type="published" when="2009-12"></date>
</publicationStmt>
<notesStmt>
<note type="content-type" subtype="brief-communication" source="shortCommunication" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</note>
<note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note>
</notesStmt>
<sourceDesc>
<biblStruct type="brief-communication">
<analytic>
<title level="a" type="main" xml:lang="en">Novel missense mutations in the
<hi rend="italic">FOXC2</hi>
gene alter transcriptional activity
<ref type="note" target="#fn1"></ref>
</title>
<title level="a" type="short" xml:lang="en">Transcriptional Activity of Mutant FOXC2</title>
<author xml:id="author-0000" role="corresp">
<persName>
<forename type="first">M.A.M.</forename>
<surname>van Steensel</surname>
</persName>
<email>m.van.steensel@mumc.nl</email>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
<affiliation>Department of Dermatology, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht</affiliation>
</author>
<author xml:id="author-0001">
<persName>
<forename type="first">R.J.</forename>
<surname>Damstra</surname>
</persName>
<affiliation>Nij Smellinghe Hospital, Drachten, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0002">
<persName>
<forename type="first">M.</forename>
<surname>Heitink</surname>
</persName>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0003">
<persName>
<forename type="first">R.S.</forename>
<surname>Bladergroen</surname>
</persName>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0004">
<persName>
<forename type="first">J.</forename>
<surname>Veraart</surname>
</persName>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0005">
<persName>
<forename type="first">Peter M.</forename>
<surname>Steijlen</surname>
</persName>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
</author>
<author xml:id="author-0006">
<persName>
<forename type="first">M.</forename>
<surname>van Geel</surname>
</persName>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands
<address>
<country key="NL"></country>
</address>
</affiliation>
</author>
<idno type="istex">EBEC66DF465A6B45C9A38C952C033F01B5A0B702</idno>
<idno type="DOI">10.1002/humu.21127</idno>
<idno type="unit">HUMU21127</idno>
<idno type="toTypesetVersion">file:HUMU.HUMU21127.pdf</idno>
</analytic>
<monogr>
<title level="j" type="main">Human Mutation</title>
<title level="j" type="alt">HUMAN MUTATION</title>
<idno type="pISSN">1059-7794</idno>
<idno type="eISSN">1098-1004</idno>
<idno type="book-DOI">10.1002/(ISSN)1098-1004</idno>
<idno type="book-part-DOI">10.1002/humu.v30:12</idno>
<idno type="product">HUMU</idno>
<imprint>
<biblScope unit="vol">30</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="E1002">E1002</biblScope>
<biblScope unit="page" to="E1009">E1009</biblScope>
<biblScope unit="page-count">8</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2009-12"></date>
</imprint>
</monogr>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<abstract xml:lang="en" style="main">
<head>Abstract</head>
<p>Mutations in the
<hi rend="italic">FOXC2</hi>
gene that codes for a forkhead transcription factor are associated with primary lymphedema that usually develops around puberty. Associated abnormalities include distichiasis and, very frequently, superficial and deep venous insufficiency. Most mutations reported so far either truncate the protein or are missense mutations in the forkhead domain causing a loss of function. The haplo‐insufficient state is associated with lymphatic hyperplasia in mice as well as in humans. We analyzed the
<hi rend="italic">FOXC2</hi>
gene in 288 patients with primary lymphedema and found 11 pathogenic mutations, of which 9 are novel. Of those, 5 were novel missense mutations of which 4 were located outside of the forkhead domain. To examine their pathogenic potential we performed a transactivation assay using a luciferase reporter construct driven by
<hi rend="italic">FOXC1</hi>
response elements. We found that the mutations outside the forkhead domain cause a gain of function as measured by luciferase activity. Patient characteristics conform to previous reports with the exception of distichiasis, which was found in only 2 patients out of 11.
<hi rend="italic">FOXC2</hi>
mutations causing lymphedema‐distichiasis syndrome reported thus far result in haplo‐insufficiency and lead to lymphatic hyperplasia. Our results suggest that gain‐of‐function mutations may also cause lymphedema. One would expect that in this case, lymphatic hypoplasia would be the underlying abnormality. Patients with activating mutations might present with Meige disease. © 2009 Wiley‐Liss, Inc.</p>
</abstract>
<textClass>
<keywords xml:lang="en">
<term xml:id="kwd1">FOXC2</term>
<term xml:id="kwd2">lymphedema</term>
<term xml:id="kwd3">transactivation</term>
<term xml:id="kwd4">forkhead</term>
<term xml:id="kwd5">Meige</term>
</keywords>
<classCode scheme="articleCategory">Mutation in Brief</classCode>
<classCode scheme="tocHeading1">Mutations in Brief</classCode>
</textClass>
<langUsage>
<language ident="EN"></language>
</langUsage>
</profileDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item>
<extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/EBEC66DF465A6B45C9A38C952C033F01B5A0B702/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata>
<istex:metadataXml wicri:clean="Wiley component found">
<istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration>
<istex:document>
<component version="2.0" type="serialArticle" xml:lang="en">
<header>
<publicationMeta level="product">
<publisherInfo>
<publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName>
<publisherLoc>Hoboken</publisherLoc>
</publisherInfo>
<doi registered="yes">10.1002/(ISSN)1098-1004</doi>
<issn type="print">1059-7794</issn>
<issn type="electronic">1098-1004</issn>
<idGroup>
<id type="product" value="HUMU"></id>
</idGroup>
<titleGroup>
<title type="main" xml:lang="en" sort="HUMAN MUTATION">Human Mutation</title>
<title type="short">Hum. Mutat.</title>
</titleGroup>
</publicationMeta>
<publicationMeta level="part" position="120">
<doi origin="wiley" registered="yes">10.1002/humu.v30:12</doi>
<numberingGroup>
<numbering type="journalVolume" number="30">30</numbering>
<numbering type="journalIssue">12</numbering>
</numberingGroup>
<coverDate startDate="2009-12">December 2009</coverDate>
</publicationMeta>
<publicationMeta level="unit" type="shortCommunication" position="17" status="forIssue">
<doi origin="wiley" registered="yes">10.1002/humu.21127</doi>
<idGroup>
<id type="unit" value="HUMU21127"></id>
</idGroup>
<countGroup>
<count type="pageTotal" number="8"></count>
</countGroup>
<titleGroup>
<title type="articleCategory">Mutation in Brief</title>
<title type="tocHeading1">Mutations in Brief</title>
</titleGroup>
<copyright ownership="publisher">© 2009 Wiley‐Liss, Inc.</copyright>
<eventGroup>
<event type="manuscriptReceived" date="2009-06-24"></event>
<event type="manuscriptAccepted" date="2009-08-26"></event>
<event type="firstOnline" date="2009-09-16"></event>
<event type="publishedOnlineFinalForm" date="2009-11-22"></event>
<event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2009-09-16"></event>
<event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:Header result:Header" date="2011-02-24"></event>
<event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-27"></event>
<event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-23"></event>
</eventGroup>
<numberingGroup>
<numbering type="pageFirst">E1002</numbering>
<numbering type="pageLast">E1009</numbering>
</numberingGroup>
<correspondenceTo>Department of Dermatology, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht</correspondenceTo>
<linkGroup>
<link type="toTypesetVersion" href="file:HUMU.HUMU21127.pdf"></link>
</linkGroup>
</publicationMeta>
<contentMeta>
<countGroup>
<count type="figureTotal" number="4"></count>
<count type="tableTotal" number="1"></count>
<count type="referenceTotal" number="13"></count>
</countGroup>
<titleGroup>
<title type="main" xml:lang="en">Novel missense mutations in the
<i>FOXC2</i>
gene alter transcriptional activity
<link href="#fn1"></link>
</title>
<title type="short" xml:lang="en">Transcriptional Activity of Mutant
<fi>FOXC2</fi>
</title>
</titleGroup>
<creators>
<creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af3" corresponding="yes">
<personName>
<givenNames>M.A.M.</givenNames>
<familyName>van Steensel</familyName>
</personName>
<contactDetails>
<email>m.van.steensel@mumc.nl</email>
</contactDetails>
</creator>
<creator xml:id="au2" creatorRole="author" affiliationRef="#af2">
<personName>
<givenNames>R.J.</givenNames>
<familyName>Damstra</familyName>
</personName>
</creator>
<creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af3">
<personName>
<givenNames>M.</givenNames>
<familyName>Heitink</familyName>
</personName>
</creator>
<creator xml:id="au4" creatorRole="author" affiliationRef="#af1 #af3">
<personName>
<givenNames>R.S.</givenNames>
<familyName>Bladergroen</familyName>
</personName>
</creator>
<creator xml:id="au5" creatorRole="author" affiliationRef="#af1 #af3">
<personName>
<givenNames>J.</givenNames>
<familyName>Veraart</familyName>
</personName>
</creator>
<creator xml:id="au6" creatorRole="author" affiliationRef="#af1 #af3">
<personName>
<givenNames>Peter M.</givenNames>
<familyName>Steijlen</familyName>
</personName>
</creator>
<creator xml:id="au7" creatorRole="author" affiliationRef="#af1 #af3">
<personName>
<givenNames>M.</givenNames>
<familyName>van Geel</familyName>
</personName>
</creator>
</creators>
<affiliationGroup>
<affiliation xml:id="af1" countryCode="NL" type="organization">
<unparsedAffiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af2" countryCode="NL" type="organization">
<unparsedAffiliation>Nij Smellinghe Hospital, Drachten, the Netherlands</unparsedAffiliation>
</affiliation>
<affiliation xml:id="af3" countryCode="NL" type="organization">
<unparsedAffiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</unparsedAffiliation>
</affiliation>
</affiliationGroup>
<keywordGroup xml:lang="en" type="author">
<keyword xml:id="kwd1">FOXC2</keyword>
<keyword xml:id="kwd2">lymphedema</keyword>
<keyword xml:id="kwd3">transactivation</keyword>
<keyword xml:id="kwd4">forkhead</keyword>
<keyword xml:id="kwd5">Meige</keyword>
</keywordGroup>
<fundingInfo>
<fundingAgency>Maastricht University Medical Center; GROW Research School for Oncology and Developmental Biology</fundingAgency>
</fundingInfo>
<fundingInfo>
<fundingAgency>ZONMW</fundingAgency>
<fundingNumber>ZONMW 907‐00‐202</fundingNumber>
</fundingInfo>
<fundingInfo>
<fundingAgency>Dutch Cancer Society</fundingAgency>
<fundingNumber>KWF UM 2009‐4352</fundingNumber>
</fundingInfo>
<abstractGroup>
<abstract type="main" xml:lang="en">
<title type="main">Abstract</title>
<p>Mutations in the
<i>FOXC2</i>
gene that codes for a forkhead transcription factor are associated with primary lymphedema that usually develops around puberty. Associated abnormalities include distichiasis and, very frequently, superficial and deep venous insufficiency. Most mutations reported so far either truncate the protein or are missense mutations in the forkhead domain causing a loss of function. The haplo‐insufficient state is associated with lymphatic hyperplasia in mice as well as in humans. We analyzed the
<i>FOXC2</i>
gene in 288 patients with primary lymphedema and found 11 pathogenic mutations, of which 9 are novel. Of those, 5 were novel missense mutations of which 4 were located outside of the forkhead domain. To examine their pathogenic potential we performed a transactivation assay using a luciferase reporter construct driven by
<i>FOXC1</i>
response elements. We found that the mutations outside the forkhead domain cause a gain of function as measured by luciferase activity. Patient characteristics conform to previous reports with the exception of distichiasis, which was found in only 2 patients out of 11.
<i>FOXC2</i>
mutations causing lymphedema‐distichiasis syndrome reported thus far result in haplo‐insufficiency and lead to lymphatic hyperplasia. Our results suggest that gain‐of‐function mutations may also cause lymphedema. One would expect that in this case, lymphatic hypoplasia would be the underlying abnormality. Patients with activating mutations might present with Meige disease. © 2009 Wiley‐Liss, Inc.</p>
</abstract>
</abstractGroup>
</contentMeta>
<noteGroup>
<note xml:id="fn1">
<p>Communicated by Sergio Ottolenghi.</p>
</note>
</noteGroup>
</header>
</component>
</istex:document>
</istex:metadataXml>
<mods version="3.6">
<titleInfo lang="en">
<title>Novel missense mutations in the FOXC2 gene alter transcriptional activity</title>
</titleInfo>
<titleInfo type="abbreviated" lang="en">
<title>Transcriptional Activity of Mutant FOXC2</title>
</titleInfo>
<titleInfo type="alternative" contentType="CDATA" lang="en">
<title>Novel missense mutations in the FOXC2 gene alter transcriptional activity</title>
</titleInfo>
<name type="personal">
<namePart type="given">M.A.M.</namePart>
<namePart type="family">van Steensel</namePart>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</affiliation>
<affiliation>Department of Dermatology, Maastricht University Medical Center, PO Box 5800, 6202 AZ Maastricht</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">R.J.</namePart>
<namePart type="family">Damstra</namePart>
<affiliation>Nij Smellinghe Hospital, Drachten, the Netherlands</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">M.</namePart>
<namePart type="family">Heitink</namePart>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">R.S.</namePart>
<namePart type="family">Bladergroen</namePart>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">J.</namePart>
<namePart type="family">Veraart</namePart>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">Peter M.</namePart>
<namePart type="family">Steijlen</namePart>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal">
<namePart type="given">M.</namePart>
<namePart type="family">van Geel</namePart>
<affiliation>Departments of dermatology, Maastricht University Medical Center, Maastricht, the Netherlands</affiliation>
<affiliation>GROW research school for oncology and developmental biology, University of Maastricht, Maastricht, the Netherlands</affiliation>
<role>
<roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="brief-communication" displayLabel="shortCommunication"></genre>
<originInfo>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<place>
<placeTerm type="text">Hoboken</placeTerm>
</place>
<dateIssued encoding="w3cdtf">2009-12</dateIssued>
<dateCaptured encoding="w3cdtf">2009-06-24</dateCaptured>
<dateValid encoding="w3cdtf">2009-08-26</dateValid>
<copyrightDate encoding="w3cdtf">2009</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<internetMediaType>text/html</internetMediaType>
<extent unit="figures">4</extent>
<extent unit="tables">1</extent>
<extent unit="references">13</extent>
</physicalDescription>
<abstract lang="en">Mutations in the FOXC2 gene that codes for a forkhead transcription factor are associated with primary lymphedema that usually develops around puberty. Associated abnormalities include distichiasis and, very frequently, superficial and deep venous insufficiency. Most mutations reported so far either truncate the protein or are missense mutations in the forkhead domain causing a loss of function. The haplo‐insufficient state is associated with lymphatic hyperplasia in mice as well as in humans. We analyzed the FOXC2 gene in 288 patients with primary lymphedema and found 11 pathogenic mutations, of which 9 are novel. Of those, 5 were novel missense mutations of which 4 were located outside of the forkhead domain. To examine their pathogenic potential we performed a transactivation assay using a luciferase reporter construct driven by FOXC1 response elements. We found that the mutations outside the forkhead domain cause a gain of function as measured by luciferase activity. Patient characteristics conform to previous reports with the exception of distichiasis, which was found in only 2 patients out of 11. FOXC2 mutations causing lymphedema‐distichiasis syndrome reported thus far result in haplo‐insufficiency and lead to lymphatic hyperplasia. Our results suggest that gain‐of‐function mutations may also cause lymphedema. One would expect that in this case, lymphatic hypoplasia would be the underlying abnormality. Patients with activating mutations might present with Meige disease. © 2009 Wiley‐Liss, Inc.</abstract>
<note type="content">*Communicated by Sergio Ottolenghi.</note>
<note type="funding">Maastricht University Medical Center; GROW Research School for Oncology and Developmental Biology</note>
<note type="funding">ZONMW - No. ZONMW 907‐00‐202; </note>
<note type="funding">Dutch Cancer Society - No. KWF UM 2009‐4352; </note>
<subject lang="en">
<genre>keywords</genre>
<topic>FOXC2</topic>
<topic>lymphedema</topic>
<topic>transactivation</topic>
<topic>forkhead</topic>
<topic>Meige</topic>
</subject>
<relatedItem type="host">
<titleInfo>
<title>Human Mutation</title>
</titleInfo>
<titleInfo type="abbreviated">
<title>Hum. Mutat.</title>
</titleInfo>
<genre type="journal">journal</genre>
<subject>
<genre>article-category</genre>
<topic>Mutation in Brief</topic>
</subject>
<identifier type="ISSN">1059-7794</identifier>
<identifier type="eISSN">1098-1004</identifier>
<identifier type="DOI">10.1002/(ISSN)1098-1004</identifier>
<identifier type="PublisherID">HUMU</identifier>
<part>
<date>2009</date>
<detail type="volume">
<caption>vol.</caption>
<number>30</number>
</detail>
<detail type="issue">
<caption>no.</caption>
<number>12</number>
</detail>
<extent unit="pages">
<start>E1002</start>
<end>E1009</end>
<total>8</total>
</extent>
</part>
</relatedItem>
<identifier type="istex">EBEC66DF465A6B45C9A38C952C033F01B5A0B702</identifier>
<identifier type="DOI">10.1002/humu.21127</identifier>
<identifier type="ArticleID">HUMU21127</identifier>
<accessCondition type="use and reproduction" contentType="copyright">© 2009 Wiley‐Liss, Inc.</accessCondition>
<recordInfo>
<recordContentSource>WILEY</recordContentSource>
<recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006E64 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 006E64 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Istex
   |étape=   Corpus
   |type=    RBID
   |clé=     ISTEX:EBEC66DF465A6B45C9A38C952C033F01B5A0B702
   |texte=   Novel missense mutations in the FOXC2 gene alter transcriptional activity
}}

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024